FAQ
Tout ce qu’il faut savoir pour devenir partenaire d’Adragos
General
Why should I choose Adragos as my CDMO partner?
At Adragos, we combine specialized development and manufacturing expertise with a flexible global network of facilities to support projects from early development through commercial supply. Our collaborative approach, experienced teams, and commitment to quality help reduce complexity, accelerate decision-making, and deliver reliable outcomes throughout your product’s lifecycle.
How does Adragos ensure quality and reliability across its global manufacturing network?
Quality is embedded in everything we do. Across all Adragos sites, we operate under harmonized quality standards, robust GMP compliance, and continuous improvement principles. While each facility brings unique capabilities and expertise, every site is aligned through shared quality systems, experienced technical teams, and a common commitment to delivering reliable products and dependable supply for our customers.
Can Adragos support both early-stage development and commercial supply?
Yes. Adragos provides integrated support across the entire product lifecycle—from formulation development and process optimization to technology transfer, scale-up, clinical manufacturing, and commercial production. By combining specialized development capabilities with commercial manufacturing expertise, we help customers move efficiently between development milestones while maintaining continuity, quality, and regulatory compliance.
How does Adragos manage technology transfer across multiple manufacturing sites?
Technology transfer is managed through close collaboration between our development, manufacturing, quality, and project management teams. We follow structured transfer processes, detailed risk assessments, and transparent communication to ensure knowledge is transferred efficiently while maintaining product quality and regulatory compliance. Our global network also provides flexibility, enabling customers to leverage specialized capabilities across multiple Adragos sites as needed.
Athens, Greece
Why should I engage Adragos Athens in the early stages of pharmaceutical development?
Engaging Adragos Athens early allows us to help shape a development strategy that supports long-term success. Our team works closely with customers to optimize formulations, assess manufacturability, and identify potential technical challenges before they become costly delays. Early collaboration helps streamline development and creates a smoother path toward clinical and commercial manufacturing.
How can the Athens team accelerate the development of Value-Added Medicines?
Our Athens team has extensive experience in developing Value-Added Medicines by combining scientific expertise with a practical approach to development. We support formulation optimization, process development, and technology selection to help customers improve existing products, differentiate their portfolios, and bring innovative therapies to market more efficiently.
Can Adragos Athens safely and efficiently support the development of highly potent (HPAPI) formulations?
Yes. Adragos Athens has dedicated expertise in developing highly potent active pharmaceutical ingredient (HPAPI) formulations. Our facilities, containment strategies, and experienced scientific teams enable us to safely manage complex development projects while maintaining high-quality standards and protecting both products and personnel throughout the development process.
How does the Athens team simplify formulation development and technology transfer?
We believe successful technology transfer starts during development. By considering future manufacturing requirements from the outset, our scientists develop robust formulations and scalable processes that simplify transfer into clinical or commercial production. Close collaboration between technical experts and project managers helps ensure a smooth transition between each stage of development.
Jura, Switzerland
Why should I choose Jura for both clinical and commercial manufacturing?
Adragos Jura offers a unique advantage by supporting both clinical and commercial manufacturing on the same production line. This integrated approach minimizes complexity, reduces project risk, and eliminates the need for unnecessary process changes as your product advances. Combined with our experienced sterile manufacturing teams and collaborative project management, Jura provides a faster and more efficient path from development to commercial supply.
Can Jura manufacture my clinical and commercial batches on the same production line?
Yes. One of Jura’s key differentiators is the ability to manufacture both clinical and commercial batches on the same production line. Unlike traditional manufacturing models that require transferring products between separate lines or facilities, Jura enables a seamless progression throughout the product lifecycle. This approach helps maintain process consistency, reduces technical risk, and shortens the timeline to commercial production.
How does Jura eliminate the need for additional technology transfer?
Because clinical and commercial manufacturing can be performed on the same production line, there is no need for a secondary technology transfer when moving into commercial production. Eliminating this additional transfer reduces project complexity, minimizes validation activities, lowers operational risk, and helps preserve process knowledge from development through commercialization.
How does Jura reduce development timelines and accelerate market entry?
By removing the need for an additional manufacturing transfer, Jura helps customers save valuable development time. Fewer transfer activities, streamlined project execution, and close collaboration between technical, manufacturing, and quality teams enable a faster transition from clinical development to commercial supply, helping products reach patients sooner.
What makes Jura a unique CDMO partner for sterile injectable manufacturing?
Jura combines flexible sterile manufacturing capabilities with a truly integrated clinical-to-commercial approach. While many CDMOs require products to move to different production lines or facilities as projects progress, Jura enables both clinical and commercial manufacturing on the same line. This unique model reduces risk, shortens timelines, improves process continuity, and provides customers with a more efficient and reliable route to commercial success.
Kawagoe, Japan
Why do global pharmaceutical companies partner with Adragos Kawagoe for manufacturing in Japan?
Adragos Kawagoe combines decades of pharmaceutical manufacturing experience with deep knowledge of the Japanese market and regulatory environment. Our team supports both domestic and international customers by delivering reliable manufacturing solutions, consistent product quality, and collaborative project management. As part of the Adragos global network, we help customers establish and grow their presence in one of the world’s most important pharmaceutical markets.
How does Kawagoe meet Japanese regulatory requirements while supporting international customers?
Our experienced teams operate in full compliance with Japanese GMP requirements while working closely with international customers to ensure smooth project execution. We provide transparent communication, structured project management, and regulatory expertise that help customers successfully navigate local requirements while maintaining alignment with their global quality expectations.
What manufacturing capabilities does Kawagoe offer for injectable and solid-dosage products?
Kawagoe offers a broad range of manufacturing capabilities for both injectable and solid-dose pharmaceutical products, supported by modern production technologies and experienced technical teams. We work with customers across different stages of the product lifecycle, delivering reliable manufacturing solutions that meet stringent quality and regulatory standards.
How does Kawagoe ensure product quality through advanced inspection and cold-chain capabilities?
Quality is supported through robust manufacturing processes, advanced inspection technologies, and controlled storage capabilities, including cold-chain management where required. Combined with comprehensive quality systems and experienced personnel, these capabilities help ensure product integrity, regulatory compliance, and reliable supply throughout the manufacturing process.
Can international clients collaborate directly with the Kawagoe team throughout their projects?
Absolutely. Our team works closely with international customers from project initiation through commercial manufacturing, providing dedicated project management and open communication at every stage. By combining local expertise with the resources of the wider Adragos network, we help customers manage complex projects efficiently while ensuring alignment across technical, quality, and regulatory teams.
Livron, France
Why is Livron the right partner for sterile liquid manufacturing projects?
Adragos Livron combines decades of manufacturing expertise with specialized capabilities in sterile liquid pharmaceuticals. Our experienced teams work closely with customers to deliver reliable manufacturing solutions that prioritize quality, regulatory compliance, and supply continuity. Whether supporting product transfers or commercial manufacturing, we focus on reducing project risk while ensuring consistent product performance.
What makes Livron unique in sterile liquids and suppository manufacturing?
Livron brings together specialized expertise in both sterile liquid injectables and suppository manufacturing at a single site. This combination of capabilities, supported by experienced technical teams and robust quality systems, enables us to provide flexible manufacturing solutions for a wide range of pharmaceutical products while maintaining the highest quality standards throughout the manufacturing process.
Can Livron provide the analytical and stability support needed throughout a product’s lifecycle?
Yes. In addition to manufacturing, Livron offers comprehensive analytical and stability services that support products from development through commercial supply. Our integrated approach helps customers maintain regulatory compliance, monitor product performance, and generate the data required to support product registration, lifecycle management, and ongoing quality assurance.
How does Livron ensure compliant handling of narcotic and controlled products?
Livron operates under stringent regulatory and quality standards for the handling of narcotic and controlled pharmaceutical products. Our qualified personnel, validated processes, and secure operating procedures ensure these products are manufactured, stored, and managed in full compliance with applicable regulatory requirements while maintaining product integrity and patient safety.
Can Livron support both development activities and long-term commercial manufacturing?
Absolutely. Livron is equipped to support customers throughout the product lifecycle, from development support and technology transfer to commercial manufacturing and ongoing supply. By combining manufacturing expertise with analytical capabilities and strong project management, we help customers transition efficiently between development stages while ensuring quality, reliability, and long-term supply continuity.
Leipzig, Germany
How can Adragos Leipzig accelerate my product’s journey to market?
Adragos Leipzig helps accelerate product development by combining technical expertise with efficient project execution. From formulation support and galenic development to technology transfer and commercial manufacturing, our experienced teams work collaboratively to reduce complexity, streamline timelines, and keep projects moving forward. With integrated development and manufacturing capabilities, we help customers reach key milestones faster while maintaining the highest quality standards.
Can Leipzig support my project from development to commercial supply?
Yes. Leipzig provides end-to-end support throughout the product lifecycle, from formulation and process development to stability studies, technology transfer, scale-up, and commercial manufacturing. By bringing these capabilities together within one experienced team, we help ensure a smooth transition between development phases while maintaining product quality, regulatory compliance, and supply continuity.
What makes Leipzig more than a manufacturing site?
Leipzig is more than a manufacturing facility; it is a development and manufacturing partner. In addition to commercial production, our experts support formulation (galenic) development, process optimization, analytical services, and stability studies to help customers build robust products and scalable manufacturing processes. This integrated approach enables earlier collaboration, faster decision-making, and a more efficient path from development to market.
How does Leipzig’s new liquid filling technology benefit my product?
Our state-of-the-art liquid filling line enhances manufacturing efficiency, flexibility, and product quality. Designed to support a wide range of liquid pharmaceutical products, it enables reliable and consistent production while meeting modern GMP requirements. Combined with our experienced technical teams, this investment allows us to support customers with efficient project implementation and dependable long-term manufacturing solutions.
Why is Leipzig the right long-term manufacturing partner for liquid and semi-solid pharmaceuticals?
Leipzig combines decades of manufacturing experience with continuous investment in modern technologies and pharmaceutical expertise. Our ability to support customers from development through commercial supply, together with our focus on quality, flexibility, and long-term partnerships, makes us a trusted manufacturing partner for liquid and semi-solid pharmaceutical products. As part of the Adragos network, we also provide the stability and resources needed to support products throughout their entire lifecycle.
Maisons-Alfort, France
Why is Maisons-Alfort considered one of France’s leading sterile manufacturing sites?
Maisons-Alfort has built a strong reputation through decades of experience in sterile manufacturing and a long-standing commitment to quality, innovation, and operational excellence. Our experienced teams, advanced manufacturing technologies, and proven track record make the site a trusted partner for pharmaceutical companies seeking reliable sterile manufacturing solutions for both regional and global markets.
What competitive advantage does Adragos Maisons-Alfort have in sterile fill-finish?
Maisons-Alfort combines advanced sterile fill-finish technologies with deep technical expertise and a highly experienced workforce. Our ability to support a broad range of sterile injectable products, together with a collaborative project approach and strong quality culture, enables us to deliver reliable manufacturing solutions tailored to each customer’s specific requirements.
How does Maisons-Alfort integrate advanced technology with decades of sterile manufacturing expertise?
State-of-the-art manufacturing technologies are only as effective as the people operating them. At Maisons-Alfort, experienced scientists, engineers, and manufacturing specialists work alongside modern aseptic production systems to ensure robust processes, consistent product quality, and efficient project execution. This combination of expertise and technology helps customers reduce risk while accelerating their path to commercial success.
Why do pharmaceutical companies trust Maisons-Alfort with their most critical sterile injectables?
Trust is built through consistent performance, technical excellence, and reliable execution. At Maisons-Alfort, every project benefits from experienced multidisciplinary teams, rigorous quality standards, and a strong focus on patient safety. We work closely with our customers to understand their product requirements and deliver manufacturing solutions that support quality, regulatory compliance, and long-term supply reliability.
How does the site ensure quality, reliability, and an uninterrupted supply of sterile medicines?
Quality and supply continuity are embedded into every stage of our operations. Robust GMP systems, experienced quality teams, proactive risk management, and continuous process improvement help ensure consistent manufacturing performance. As part of the Adragos Sterile Network, Maisons-Alfort also benefits from shared expertise and manufacturing flexibility that strengthen long-term supply resilience.
What types of complex sterile injectables can be manufactured at Maisons-Alfort?
Maisons-Alfort supports a wide range of sterile injectable products, including liquid and lyophilized formulations in vials and prefilled syringes. Our manufacturing capabilities are designed to accommodate complex pharmaceutical products while maintaining the highest standards of sterility, product quality, and regulatory compliance.
Can Maisons-Alfort support complex technology transfers from development through commercial manufacturing?
Yes. Our experienced technical, manufacturing, and project management teams have extensive expertise in managing complex technology transfer projects. Through structured planning, close customer collaboration, and robust transfer methodologies, we help ensure a smooth transition into commercial manufacturing while maintaining product quality, process consistency, and regulatory compliance.
How does Maisons-Alfort strengthen supply continuity through the Adragos Sterile Network?
Maisons-Alfort is an integral part of the Adragos Sterile Network, working alongside our sterile manufacturing sites in Jura and Livron to provide customers with greater flexibility, shared technical expertise, and enhanced business continuity. This network approach helps reduce supply risk, supports scalable manufacturing solutions, and provides customers with greater confidence throughout the lifecycle of their sterile injectable products.
